Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice

Amy Winship, Lauren R. Alesi, Sneha Sant, Jessica Stringer, Aldana Cantavenera, Teharn Saffron Hegarty, Carolina Lliberos Requesens, Seng Hii Jason Liew, Urooza Sarma, Meaghan Griffiths, Nadeen Zerafa, Stephen B. Fox, Emmaline Brown, Franco Caramia, Pirooz Zareie, Nicole La Gruta, Kelly Anne Phillips, Andreas Strasser, Sherene Loi, Karla Hutt

Research output: Contribution to journalArticleResearchpeer-review

21 Citations (Scopus)


Loss of fertility is a major concern for female reproductive-age cancer survivors, since a common side-effect of conventional cytotoxic cancer therapies is permanent damage to the ovary. While immunotherapies are increasingly becoming a standard of care for many cancers—including in the curative setting—their impacts on ovarian function and fertility are unknown. We evaluated the effect of immune checkpoint inhibitors blocking programmed cell death protein ligand 1 and cytotoxic T lymphocyte-associated antigen 4 on the ovary using tumor-bearing and tumor-free mouse models. We find that immune checkpoint inhibition increases immune cell infiltration and tumor necrosis factor-α expression within the ovary, diminishes the ovarian follicular reserve and impairs the ability of oocytes to mature and ovulate. These data demonstrate that immune checkpoint inhibitors have the potential to impair both immediate and future fertility, and studies in women should be prioritized. Additionally, fertility preservation should be strongly considered for women receiving these immunotherapies, and preventative strategies should be investigated in future studies.

Original languageEnglish
Pages (from-to)1-13
Number of pages13
JournalNature Cancer
Issue number8
Publication statusPublished - Aug 2022

Cite this